Combination of temsirolimus (CCI-779) with chemo-radiation in newly diagnosed GBM (NCCTG trial N027D) is associated with increased infectious risks1
      QxMD      Google Scholar   
Citation:
Clin Cancer Res vol 16 (22) 5573-5580
Year:
2010
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
pmc-release
Note:
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
Parents:
72   76  
Children:
None
Program:
OGC
Primary Committee:
Neuro-Onc
Sec. Committees:
   
Pharmas:
 
Grants:
U10 CA025224-25, P50 CA108961-019004, U24 CA114740-03, P50 CA108961, U10 CA025224-30S2, U10 CA025224-24S2, U10 CA025224-220017, U10 CA025224-23S1, U10 CA025224-30, U24 CA114740-04, U24 CA114740-05, U10 CA025224-28, U10 CA025224-31S1, U10 CA025224-23S10004, U24 CA114740, U24 CA114740-01, P50 CA108961-039004, CA-114740, CA-25224, U10 CA025224-28S3, U10 CA025224-29, U10 CA025224-30S3, U10 CA025224-24, U10 CA025224-28S1, U10 CA025224-31, CA-108961, U10 CA025224-27, P50 CA108961-049004, P50 CA108961-050001, P50 CA108961-010001, U10 CA025224-230004, U10 CA025224-32, P50 CA108961-029004, P50 CA108961-059004, U10 CA025224-23, P50 CA108961-020001, U10 CA025224-24S1, U10 CA025224-28S2, U24 CA114740-02, U10 CA025224-23S10017, U10 CA025224-220004, U10 CA025224, P50 CA108961-030001, P50 CA108961-040001, U24 CA114740-05S1, U10 CA025224-26, U10 CA025224-230017  
Corr. Author:
 
Authors:
                           
Networks:
 
Study
NCCTG-N027D
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
1
Keywords:
glioblastoma, immunosuppression, temsirolimus, radiation temozolomide, infection